LifeCannMD

MAY 27, 2025

A 2023 study in Cannabis and Cannabinoid Research validated this approach, showing that patients following slower titration schedules had 84% treatment satisfaction compared to 61% with faster increases. The Stanford Sleep Laboratory Findings Stanford’s Sleep Research Center studied 847 insomnia patients using different cannabis doses.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

MAY 12, 2022

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 21, 2021

Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. The company, which began trading on the OTC and Frankfurt Stock exchanges in October, has plans to open as many as 120 more clinics by 2023.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Tweet this. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

FEBRUARY 9, 2022

There’s also concern about a rare condition known as wood lover’s paralysis , a condition that produces muscle weakness a few hours after hallucinogenic mushrooms are consumed. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis. Other species might be introduced later.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Project CBD

OCTOBER 26, 2023

Goldstrich, MD, with Angela Bacca (Flower Valley Press, 2023). As part of the approval process for all markets, they have conducted critical Phase 2 studies on various conditions, including cancer. Adapted from The Cannabis Cancer Connection: How to use cannabis and hemp to kill cancer cells by Joe D.

Research and Development 349

Research and Development Cannabinoids Terpenes Pharmaceutical 349

Cannabis Law Report

MAY 29, 2022

As previously mentioned, clinical studies are promising, including a Phase 3 trial (the last step before submitting an NDA) completed last November. [9] 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] Clinical Trials and Human Subject Protections. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. The measure adds anxiety, autism, opioid addiction or dependence, anorexia nervosa, among other qualifying conditions. California. New Hampshire.

Legislation 45

Legislation Patients Access Banking 45

Veriheal

NOVEMBER 7, 2024

Because the categorization of a controlled substance determines its availability and accessibility, the benefits of rescheduling are important to patients suffering from chronic pain, epilepsy, and other conditions. In August 2023, the HHS also crucially recommended to the DEA that cannabis be relisted from Schedule I to Schedule III.

DEA 97

DEA Policy Chronic Pain Marijuana 97